Email this article Successful treatment with sorafenib in patients with advanced hepatocellular carcinoma: clinical case
- Authors: Bisovskaya Y.V1, Breder VV1, Medvedeva BM1, Gorbunova VA1
-
Affiliations:
- ФГБУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва
- Issue: Vol 16, No 2 (2014)
- Pages: 73-77
- Section: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/26969
- ID: 26969
Cite item
Abstract
Multi-kinase inhibitor sorafenib is the only one drug which increases life time in patients with advanced hepatocellular carcinoma (HCC). Results from the SHARP trial showed that median progression-free survival was less than 5 months. However, it is possible to achieve strong treatment effect for several years receiving sorafenib. Antiviral treatment in the course of the immune treatment for all patients with chronic hepatitis B (CHB) should follow the recommendations from existing The European Association for the Study of the Liver (EASL) guidelines. It is possible to prescribe constant antiviral therapy (AT) with the nucleosides analogue as a treatment (according to the indication) or for prophylactic purposes (prevention of reactivation of HBV-infection in «inactive HBsAg carriers») to prevent cirrhosis development and to prolong sorafenib therapy. New multi-kinase inhibitor sorafenib was approved for the treatment of advanced HCC in the Russian Federation (RF) in 2006. However, there is not enough information on receiving sorafenib in patients with HCC associated with CHB in the RF. Our clinical case presents long-term treatment (37 months) with sorafenib in the course of the AT in patients with HCC. This example helps us to discuss the features of modern diagnostic and treatment algorithm of HCC, chronic hepatitis B and cirrhosis in its outcome.
Full Text
##article.viewOnOriginalSite##About the authors
Yu V Bisovskaya
ФГБУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москвааспир. ФГБУ РОНЦ
V V Breder
ФГБУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москваканд. мед. наук
B M Medvedeva
ФГБУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москваканд. мед. наук
V A Gorbunova
ФГБУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москвад-р мед. наук, проф.
References
- El-Serag H.B. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterol 2012; 142: 1264-73.
- Forner A, Llovet J.M, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379: 1245-55.
- Bruix J, Barrera J.M, Calvet X et al. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 1989; 2 (8670): 1004-6.
- Shiratori Y, Shiina S, Imamura M et al. Characteristic difference of hepatocellular carcinoma between hepatitis B- and C-viral infection in Japan. Hepatology 1995; 22 (4 Pt. 1): 1027-33.
- Marrero J.A. Current Treatment Approaches in HCC. Clin Adv Hematol Oncol 2013; 11 (Suppl. 5): 15-8.
- Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-2.
- European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASLEORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-43.
- Lencioni R, Chen X.P, Dagher L, Venook A.P. Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved? Oncologist 2010; 15 (Suppl. 4): 42-52.
- Cheng A.L, Kang Y.K, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double - blind, placebo - controlled trial. Lancet Oncol 2009; 10 (1): 25-34.
- Llovet J.M, Ricci S, Mazzaferro V et al. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359 (4): 378-90.
- Forner A, Reig M.E, de Lope C.R, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 2010; 30: 61-74.
Supplementary files
